This site contains information about prescription peptide therapy protocols intended for adults. You must be 18 years of age or older to enter.
By entering, you confirm you are at least 18 years old and agree to our Terms of Service. All protocols require a valid physician prescription.
A modified fragment of human growth hormone (hGH 176-191) studied for its targeted fat-burning effects. Unlike sermorelin or tesamorelin, AOD9604 does not stimulate IGF-1 production or suppress endogenous GH — it acts directly on beta-adrenergic receptors in adipose tissue to stimulate lipolysis and inhibit fat synthesis, with no documented effect on blood glucose or insulin sensitivity.
Human growth hormone does many things: it stimulates IGF-1 production, drives protein synthesis, affects glucose metabolism, and promotes lipolysis (fat breakdown). AOD9604 is an isolate of the C-terminal fragment of hGH — specifically amino acids 176-191 with a tyrosine modification for stability — that was engineered to capture the lipolytic effects while stripping away the IGF-1 and glucose effects.
The mechanism works via β3-adrenergic receptors in white adipose tissue. Activation of β3-AR stimulates fat cell breakdown (lipolysis) and inhibits lipogenesis (new fat synthesis) — the same pathway used by native GH for fat metabolism, but through a fragment that bypasses the hypothalamic-pituitary-GH axis entirely. The pituitary is not involved. IGF-1 is not elevated. Endogenous GH production is not suppressed.
AOD9604 was developed by Metabolic Pharmaceuticals and completed Phase I and Phase II clinical trials in Australia, where it received Generally Recognized as Safe (GRAS) status from the FDA for use as a food ingredient. It did not complete Phase III trials for obesity as a drug — but the safety and tolerability data from Phase II is available and reassuring for research purposes.
β3-adrenergic activation in white adipose tissue drives fat cell breakdown. Research specifically in visceral and subcutaneous adipose depots. Effect is local and tissue-specific — not systemic metabolic disruption.
Phase II human trials showed modest but measurable fat mass reduction compared to placebo in obese subjects. Effect size was below the threshold for drug development to continue, but the directional signal was consistent.
A key differentiator: AOD9604 does not affect blood glucose, insulin secretion, or insulin sensitivity — unlike exogenous GH, which is diabetogenic at pharmacological doses. Documented across Phase I and II trials.
Because it operates downstream of the GH axis on peripheral receptors, AOD9604 does not elevate IGF-1. This separates it from tesamorelin and other GHRH/GHRP peptides where IGF-1 monitoring is advisable.
Emerging research (primarily preclinical) suggests AOD9604 may support cartilage repair and have anti-inflammatory effects in osteoarthritis models. A different research angle from its primary fat-loss application.
Because it does not affect the GH axis, AOD9604 can be combined with GHRH/GHRP peptides (tesamorelin, ipamorelin, sermorelin) without receptor competition or axis interference. Complementary mechanisms.
AOD9604 is administered subcutaneously, typically before the first meal or fasted cardio session. The most commonly referenced research dose is 300mcg daily. Phase II trials used doses ranging from 1mg to 30mg — the lower doses performed comparably to higher ones, suggesting a ceiling effect well below the highest tested doses.
| Protocol | Dose | Timing | Notes |
|---|---|---|---|
| Standard | 300mcg SC | Morning, fasted | Most referenced dose in research community. Fasted administration maximizes lipolytic signaling when insulin is low. |
| Higher range | 500mcg SC | Morning, fasted | Upper end of common research use. Phase II data showed no additional benefit beyond ~500mcg; diminishing returns above this level. |
| Cycle length | — | — | Phase II protocols ran 12 weeks. Common research cycles are 8–12 weeks with 4+ weeks off. No receptor desensitization data in humans for long-term use. |
Phase II tested doses from 1mg to 30mg/day over 12 weeks. The key finding: higher doses did not outperform lower doses — a clear ceiling effect, suggesting the β3-adrenergic pathway saturates early. Research doses (300–500mcg) operate well below the tested range.
Completed Phase I (safety) and Phase II (efficacy) trials in Australia under Metabolic Pharmaceuticals. Phase II ran 12-week protocols, establishing the cycle length convention used in current research settings.
Received Generally Recognized as Safe (GRAS) status from the FDA as a food ingredient — the same regulatory standard applied to nutrients, vitamins, and food additives. Distinct from drug approval, but reflects meaningful toxicity review.
Selectively targets β3-adrenergic receptors in white adipose tissue. β3-AR stimulation drives lipolysis and thermogenesis specifically in fat cells without the cardiovascular effects (tachycardia, blood pressure) associated with β1/β2 activation.
AOD9604's independence from the GH axis makes it freely stackable with all GH-stimulating peptides. Combining it with GHRH/GHRP peptides gives the GH pulse effects (muscle recovery, IGF-1, anabolic signaling) while AOD9604 handles the fat-specific lipolysis. Two mechanisms, one protocol:
Third-party COA, Finnrick-verified purity. Available in 5mg vials. Ships within 24 hours.
Start Protocol Intake ← All ProtocolsMedical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All protocols require evaluation and prescription by a licensed physician. You should consult a qualified healthcare provider before starting any new medical protocol. Individual results vary. Cinch Bio is not a pharmacy and does not dispense medications — all prescriptions are issued by independent licensed physicians and filled by licensed 503A compounding pharmacies.